Differences in clinical and angiographic outcomes with different drug-eluting stents in Japanese patients with and without diabetes mellitus.
BACKGROUND
Although percutaneous coronary intervention (PCI) in patients with diabetes mellitus (DM) is associated with worse clinical outcomes, the efficacy of drug-eluting stents (DES) in Japanese patients and differences in effectiveness between different DES types remain unknown.


METHODS
Five-hundred and sixty-two consecutive patients (183 with DM, 379 without DM) with 676 lesions were treated with sirolimus-eluting stents (SES, n=531; 160 DM group, 371 non-DM group) or paclitaxel-eluting stents (PES, n=145; 64 and 81, respectively). We assessed the initial and 8-month follow-up clinical and angiographic outcomes.


RESULTS
There were no significant differences in clinical and lesion characteristics, although the pre-minimum luminal diameter was smaller in the DM group (p=0.016). The risk of major adverse cardiac events (MACE), defined as cardiac death, non-fatal myocardial infarction, congestive heart failure, or recurrent angina pectoris, was higher in the DM group compared with the non-DM group (17.4% vs 9.5%, p=0.007). Among diabetic patients, although SES reduced late loss by 0.45 mm (p<0.001) and the binary restenosis rate by 66.4% (7.4% vs 22.0%, p<0.001) compared with PES at 8 months, it did not reduce target lesion revascularization or MACE, as in the non-DM group.


CONCLUSIONS
Diabetic patients have worse mid-term prognosis than non-diabetic patients undergoing PCI with DES. Although the superiority of SES in terms of late loss or restenosis may not play a clinically meaningful role in the treatment of diabetic patients, this phenomenon was independent of the presence of diabetes.
Department of Cardiology, Japanese Red Cross Okayama Hospital, Okayama, Japan. tesato@ta3.so-net.ne.jp
Tetsuya
T
Sato
Tamaki
T
Ono
Yoshimasa
Y
Morimoto
Haruaki
H
Kawai
Soichiro
S
Fuke
Tetsuya
T
Ikeda
Hironori
H
Saito
D000368:Aged; D000369:Aged, 80 and over; D044466:Asian People; D017023:Coronary Angiography; D003327:Coronary Disease / Q000150:complications / Q000000981:diagnostic imaging* / Q000628:therapy*; D023903:Coronary Restenosis / Q000209:etiology / Q000517:prevention & control; D048909:Diabetes Complications; D054855:Drug-Eluting Stents / Q000009:adverse effects*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects*; D011379:Prognosis; D012189:Retrospective Studies; D020123:Sirolimus; D016896:Treatment Outcome
D017239:Paclitaxel; D020123:Sirolimus